Yishengtai (beinaglutide) / Shanghai Benemae Pharma - LARVOL DELTA

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients (clinicaltrials.gov) - P=N/A | N=115 | Recruiting | Sponsor: Beijing Hospital | Unknown status ➔ Recruiting | N=260 ➔ 115 | Trial completion date: Dec 2021 ➔ Dec 2025 | Trial primary completion date: Jun 2021 ➔ Sep 2025

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Expert Rev Endocrinol Metab) - "In addition, body weight loss was greater in doses < 0.4 mg compared to doses ≥ 0.4 mg. The results of this meta-analysis show that Beinaglutide is effective in reducing parameters related to obesity, TG as well as SBP."

Journal • Retrospective data • Review • Genetic Disorders • Infectious Disease • Obesity

A randomized controlled study comparing the clinical pregnancy rates of Beinaglutide Injection combined with metformin and metformin monotherapy in overweight/obese patients with polycystic ovary syndrome (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; Shanghai First Maternity and Infant Hospital, Tongji University Sc

New P4 trial • Obesity • Polycystic Ovary Syndrome

The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis. (PubMed, Diabetol Metab Syndr) - "The results of this meta-analysis show that Beinaglutide is effective in reducing factors related to obesity, TG as wll as SBP, especially with longer interventions and lower doses."

Journal • Retrospective data • Genetic Disorders • Infectious Disease • Obesity

Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity (clinicaltrials.gov) - P=N/A | N=392 | Not yet recruiting | Sponsor: Peking University Third Hospital

New trial • Genetic Disorders • Infertility • Obesity • Polycystic Ovary Syndrome • Sexual Disorders

An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review. (PubMed, Diabetes Obes Metab) - "Semaglutide and beinaglutide biosimilars are currently under investigation as well. With the growing popularity of GLP-1 RAs, accessibility and affordability remain a challenge as monthly costs without insurance for liraglutide, semaglutide and tirzepatide are $1418, $892, and $974 respectively...Preliminary results from liraglutide biosimilars are promising, and several semaglutide biosimilars are currently being investigated. Future research should focus on conducting comparative head-to-head trials to determine the clinical outcomes between biosimilars and reference products."

Journal • Review • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis. (PubMed, BMJ Open) - "Implementation of NDPN and NCDP had successfully cut-off the price of novel hypoglycaemic drugs and significantly increased their utilisation. In the future, the government needs to control pharmaceutical expenses more strictly while ensuring the rational use of the drugs."

Journal • Diabetes • Endocrine Disorders • Metabolic Disorders

Comparison of the effects of benaglutide or metformin treatment on endocrine metabolism and pregnancy in overweight/obese patients with polycystic ovary syndrome (ChiCTR) - P=N/A | N=154 | Recruiting | Sponsor: The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University

New trial • Obesity • Polycystic Ovary Syndrome

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. (PubMed, Metabolism) - "Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial. (PubMed, Front Pharmacol) - "The safety profile and pharmacokinetic properties support further development and clinical applications of beinaglutide as an anti-obesity drug. [https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000BPEI&selectaction=Edit&uid=U00050YQ&ts=2&cx=wy0ioj]."

Journal • P1 data • PK/PD data • Genetic Disorders • Obesity • Type 2 Diabetes Mellitus

Metabolomics and molecular docking-directed anti-obesity study of the ethanol extract from Gynostemma pentaphyllum (Thunb.) Makino. (PubMed, J Ethnopharmacol) - "The extract of G. pentaphyllum can inhibit the absorption of tryptophan and its conversion to 5-HT through the Slc6a19/Tph1 pathway, upregulating the expression of Ucp1, thereby promoting thermogenesis in brown adipose tissue, facilitating weight loss, and mitigating symptoms of fatty liver. Triterpenoids such as Araliasaponin I, identified in GPE, could be the potential inhibitor of Tph1 and responsible for the anti-obesity activities."

Journal • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity • SLC6A19

Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. (PubMed, Risk Manag Healthc Policy) - "The final assessment result scores from highest to lowest were semaglutide (71.5 points), dulaglutide (68.9 points), liraglutide (68.7 points), exenatide (62.5 points), lixisenatide (59.9 points), polyethylene glycol loxenatide (55.9 points), and benaglutide (45.1 points). When a healthcare organization introduces GLP-1RAs to their hospital, they can refer to the assessment results and use the top three recommended medications: semaglutide, dulaglutide, and liraglutide."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial. (PubMed, Front Endocrinol (Lausanne)) - "Beinaglutide may offer the potential for a disease-modifying intervention in cardiovascular disease (CVD). www.chictr.org.cn, identifier ChiCTR2200061003."

Clinical • Journal • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial. (PubMed, Diabetes Obes Metab) - No abstract available

Journal • Diabetes • Hepatology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Type 2 Diabetes Mellitus

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. (PubMed, Diabetes Obes Metab) - "Beinaglutide combined with lifestyle intervention resulted in significant and clinically meaningful weight reduction with good tolerance in non-diabetic Chinese individuals with overweight or obesity."

Clinical • Journal • P3 data • Genetic Disorders • Obesity • Pancreatitis

The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial. (PubMed, J Diabetes) - P=N/A | "Beinaglutide exhibited a favorable hypoglycemic effect on patients with T2DM, and in combination with IGlar, glucose level was further decreased. Low fasting C-peptide in patients may reduce the glycemic response to beinaglutide therapy. We recommend that C-peptide levels be evaluated when using or switching to the novel glucagon-like peptide-1 receptor agonists beinaglutide."

Clinical • Combination therapy • Journal • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus